Tiziana Life Sciences PLC’s Quiet Period To End on December 31st (NASDAQ:TLSA)

Tiziana Life Sciences’ (NASDAQ:TLSA) quiet period is set to end on Monday, December 31st. Tiziana Life Sciences had issued 442,910 shares in its public offering on November 20th. The total size of the offering was $4,384,809 based on an initial share price of $9.90. During Tiziana Life Sciences’ quiet period, insiders and underwriters involved in the IPO are restricted from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the end of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

A number of equities analysts have weighed in on the company. Laidlaw assumed coverage on Tiziana Life Sciences in a research note on Monday, December 17th. They set a “buy” rating on the stock. HC Wainwright reissued a “buy” rating on shares of Tiziana Life Sciences in a research note on Friday, December 14th.

NASDAQ TLSA opened at $7.31 on Friday. Tiziana Life Sciences has a fifty-two week low of $6.61 and a fifty-two week high of $12.17.

TRADEMARK VIOLATION WARNING: This piece was published by WKRB News and is the sole property of of WKRB News. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.wkrb13.com/2018/12/28/tiziana-life-sciences-plcs-quiet-period-to-end-on-december-31st-nasdaqtlsa.html.

Tiziana Life Sciences Company Profile

Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of therapeutics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Milciclib (TZLS-201) that is in phase II clinical trials for epithelial thymic carcinoma and/or thymoma in patients previously treated with chemotherapy; and Foralumab (TZLS-401), a human anti-CD3 antibody, which completed phase IIa clinical trials for autoimmune and inflammatory diseases, such as non-alcoholic steatohepatitis, primary biliary cholangitis, ulcerative colitis, multiple sclerosis, autoimmune type-1 diabetes, inflammatory bowel diseases, and lupus.

Recommended Story: What is the NASDAQ?

Receive News & Ratings for Tiziana Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply